No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis

Autor: Cornelia F Allaart, Charlotte M. Nusman, Taco W. Kuijpers, D. M. C. Brinkman, R. ten Cate, P. C. E. Hissink Muller, M. A. J. van Rossum, Y. Koopman-Keemink, D. Schonenberg-Meinema, L.W.A. van Suijlekom-Smit, Sytske Anne Bergstra, J.M. van den Berg, W. G. van Braak, D. Schreurs, Mario Maas, Robert Hemke
Přispěvatelé: Radiology and Nuclear Medicine, AII - Inflammatory diseases, AMS - Ageing & Morbidty, AMS - Sports & Work, Graduate School, Paediatric Infectious Diseases / Rheumatology / Immunology, General Paediatrics, AGEM - Endocrinology, metabolism and nutrition, ARD - Amsterdam Reproduction and Development, Pediatrics, APH - Aging & Later Life
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Pediatric rheumatology online journal, 17(1):62. BioMed Central
Pediatric Rheumatology, 17(1):62. BioMed Central Ltd.
Pediatric Rheumatology, 17(1)
Pediatric Rheumatology Online Journal
Pediatric Rheumatology. Springer
Pediatric Rheumatology
Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-10 (2019)
ISSN: 1546-0096
DOI: 10.1186/s12969-019-0362-1
Popis: Background To evaluate radiographic progression of patients with new-onset juvenile idiopathic arthritis (JIA) in response to an early, tightly-controlled, treatment-to-target. Methods Patients with JIA participating in the BeSt-for-Kids-study, randomized to 3 treatment strategy arms, were eligible if at least 1 conventional wrist-radiograph was available. Bone damage as reflected by carpal length was assessed using the Poznanski-score. The BoneXpert-method was used to determine the Bone Age (BA, > 5 years) and bone mineral density (BMD) of the wrist. These scores were evaluated over time and compared between the treatment arms and mean JADAS10-score using linear mixed models corrected for age and symptom duration. Results In 60 patients, 252 radiographs were analysed. Baseline age and symptom duration were different between the arms. No difference in comparison to the healthy reference population was found at baseline for the Poznanski-score (IQR varying from − 0,82; 0.68), nor for BA (varying from − 0.88 to 0.74). Baseline BMD was statistically significantly lower in arm 3 (initial treatment with etanercept and methotrexate) (− 1.48; − 0.68) compared to arm 1 (− 0.84; − 0.04) and arm 2 (− 0.93; 0.15). After treatment to target inactive disease, the Poznanski-scores and the BA remained clinically unchanged, while the BMD in arm 3 improved (p
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje